Financial
News release
TopTOKYO, JAPAN – May 15, 2023 – Terumo Corporation (TSE: 4543) today announced that it will construct a new manufacturing facility for the Medical Care Solutions Company in the premises of the Kofu Factory located in Yamanashi, Japan. The total investment will be 52.2 billion JPY, and the construction will be completed in fiscal year 2025. Once operation starts, the new manufacturing facility will be utilized for the contract development and manufacturing organization (CDMO) business, as well as products related to peritoneal dialysis. In addition, the new facility will also provide additional spaces that allows the company to scale-up production to meet future demands.
Terumo will continue to contribute to better patient care and transformation by further enhancing our solutions that leverage the strengths it has cultivated over the years, thereby providing “yasashii*” medical care for everyone involved in healthcare.
About Terumo's CDMO Business
Terumo's CDMO business provides integrated support for drug-device combination products ranging from design to commercial manufacturing through partnerships with pharmaceutical companies. Terumo develops devices that combine material technologies suitable for drugs and delivers combination products utilizing its advanced manufacturing technologies. Terumo has expanded the CDMO business globally since last year to seize the rapidly growing demand from pharmaceutical companies outside of Japan.
In addition, Terumo is now collaborating with Eisai Co., Ltd. (Headquarters: Tokyo, Japan) to co-develop a new drug-device combination product (autoinjector formulation) for the Alzheimer’s disease treatment that is being developed by Eisai.
The CDMO business is one of the growth pillars of GS26, Terumo’s 5-Year Growth Strategy that began in fiscal year 2022. To support the strategy, Terumo will strive to strengthen and optimize production capacity to meet customer demands globally.
In addition, Terumo is now collaborating with Eisai Co., Ltd. (Headquarters: Tokyo, Japan) to co-develop a new drug-device combination product (autoinjector formulation) for the Alzheimer’s disease treatment that is being developed by Eisai.
The CDMO business is one of the growth pillars of GS26, Terumo’s 5-Year Growth Strategy that began in fiscal year 2022. To support the strategy, Terumo will strive to strengthen and optimize production capacity to meet customer demands globally.
About Terumo’s Peritoneal Dialysis Business
Terumo promotes peritoneal dialysis therapy, which offers a greater lifestyle flexibility for patients to maintain their lifestyle. In order to provide easy and safe peritoneal dialysis therapy to the increasing number of elderly peritoneal dialysis patients, Terumo provides devices that are designed for easy use and reduction of infection risk, as well as dialysis solutions that reduce the burden on the patient's body.
With the construction of the new manufacturing facility, Terumo will strive to contribute to the improvement of the quality of peritoneal dialysis therapy, meet the expected increase in product demand, and ultimately to contribute to “yasashii” medical care that touches patients' lives.
With the construction of the new manufacturing facility, Terumo will strive to contribute to the improvement of the quality of peritoneal dialysis therapy, meet the expected increase in product demand, and ultimately to contribute to “yasashii” medical care that touches patients' lives.
* “Yasashii” is a Japanese term that suggests a combination of kind, caring, friendly, and thoughtful.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.